INVESTIGATION OF SERUM CYSTEINE CONCENTRATION TO MONITOR GLOMERULAR FILTRATION RATE FOR EARLY DIAGNOSIS OF ACUTE KIDNEY INJURY IN PATIENTS WITH COMBINED TRAUMA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim/ To determine the early diagnostic criteria for acute kidney injury in patients with combined trauma using serum cystatin C as a biomarker in the diagnostic work-up of the affected patients. Materials and methods/ The study comprised 42 patients who suffered combined trauma from 2015 to 2016. Cystatin C level was measured in serum. Blood sampling was done on the 1st, 3rd, 7th, 14th day of the injury. The patients were predominantly men (80%). Renal function was tested by measuring the rate of filtration and reabsorption using the Reberg-Tareev test. All patients were tested for the following parameters: serum and urine creatinine, 1-minute, 1-hour and 24-hour urine output, the rate of glomerular filtration and tubular reabsorption. Results and discussion/ Forty (95.3%) patients had normal Reberg-Tareev test values. In 2 (4.7%) patients Reberg-Tareev test results were below normal values, which was associated with the development of acute renal failure on the sixth or seventh day after trauma. The overwhelming majority of patients with combined trauma had a normal serum creatinine level (n=38). In 33 (78.6%) patients serum cystatin C level was more than 30 percent above normal values. Moreover, an increase in the cystatin C level was observed in the first 3 days, with a gradual decrease thereafter. The glomerular filtration rate, according to the Reberg-Tareev test was reduced only in 4 patients, but when the Hawk formula was used to calculate GFR, it was reduced in 33 patients. On the 3rd day after trauma, based on the increase in the serum cystatin level, 12 patients were found to have subclinical acute renal damage. At the same time, this group of patients had normal azotemia parameters. These findings suggest that measuring glomerular filtration rate using serum cystatin C has a greater accuracy in detecting latent renal dysfunction.

Full Text

Restricted Access

About the authors

I. A Miziev

H. M. Berbekov Kabardino-Balkar State University

Dr.Med.Sci., Prof., Academician of the RANS, the Honored Scientist ofKabardino-Balkar Republic, Head ofthe Department of Faculty and Endoscopic Surgery Nalchik, Russia

M. Kh Makhov

H. M. Berbekov Kabardino-Balkar State University

Email: mahov_murat@mail.ru
Ph.D. Student at the Department of Faculty and Endoscopic Surgery Nalchik, Russia

References

  1. Каюков И.Г. Почему скорость клубочковой фильтрации, а не концентрация креатинина в сыворотке крови? Нефрология. 2004;4(4):99-102
  2. Каюков И.Г., Смирнов А.В., Эмануэль В.Л. Цистатин в современной медицине. Нефрология. 2012;16(1):22-39
  3. Смирнов А.В. и др. Проблема оценки клубочковой фильтрации в современной нефрологии: новый индикатор - цистатин С. Нефрология. 2005;9(3):16-27
  4. Смирнов А.В. и др. Проблемы диагностики и стратификации тяжести острого повреждения почек. Нефрология. 2009;13(3):9-18
  5. Mussap M. et al. Cystatin C is more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int. 2002;61:1453-1461.
  6. Вельков В.В. Цистатин С: новые возможности и новые задачи для лабораторной диагностики (часть 1). Клинико-лабораторный консилиум. 2010;36(5):23-32
  7. Вельков В.В. Цистатин С: новые возможности и новые задачи для лабораторной диагностики (часть 2). Клинико-лабораторный консилиум. 2011;37(1):27-38
  8. Coca S.G. et al. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 2008;73(9):1008-1016.
  9. Filler G. et al. Cystatin C as a marker of GFR - history, indications, and future research. Clin. Biochem. 2005;38(1):1-8.
  10. Devarajan P. Emerging urinary biomarkers in the diagnosis of acute kidney injury. Expert. Opin. Med. Diagn. 2008;2(4):387-398.
  11. Perlemoine C. et al. Interest of cystatin C in screening diabetic patients for early impairment of renal function. Metabolism. 2003;52(10):1258-1264.
  12. Herget-Rosenthal S. et al. Measurement of urinary cystain C by particle enhanced nephelometric immunoassay: precision, interferences, stability, and reference range. Ann. Clin. Biochem. 2004;41:111-118.
  13. Bland J.M., Aliman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
  14. Aruoma O.I., Halliwell В., Ноеу В.М., Bucler J. The antioxidart action of N-acetylcysteine: its reaction with hydrogen peroxide, hvdroxyl radical, superoxide, and hypochlorous acid. Free Radic. Biol. Med. 1989;6(6):593- 597.
  15. Decramer M., Rutten-van Mzlken M., Dekhuijzen P.N.R. et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo controlled Trial. Lancet. 2005;365:1552-1560.
  16. Demedts M., Behr J. et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Eng. J. Med. 2005;353:2229-2242.
  17. Droge W. Cysteine and glutathione deficiency in AIDS patients: a rationale for the treatment with N-acetylcysteine. Pharmacology. 1993;46:61-65.
  18. Eklund A., Eriksson O., Hakansson L. et al. Oral N-acetylcystein reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables. Eur. Respir. J. 1988;1:832-838.
  19. Feldman L., Efrati S. et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int. 2007.
  20. Fiorentini С., Falzano L., Rivabene R., Fabbri A., Malorni W. N-acetylcysteine protects epithelial cells against the oxidative imbalance due со Clostridium difficile toxins. FEBS Lett. 1999;453(1-2):124-128.
  21. Gorda I.I., Bezrodnyi A.B., Vasilenko O.V., Dan’kevich I.V. Markers of acute renal injury. Sertseisudini. 2012;3:108-113. Russian (Горда И.И., Безродный А.Б., Василенко О.В., Данькевич И.В. Маркеры острого повреждения почек. Серцеюудини. 2012;3:108-113).
  22. Murray P.T., Devarajan P., Levey A.S., Eckardt K.U., Bonventre J.V., Lombardi R., Herget-Rosenthal S., Levin A. A framework and key research questions in AKI diagnosis and staging in different environments. Clin. J. Am. Soc. Nephrol. 2008;3:864-868.
  23. Zahran A., El-Husseini A., Shoker A. Can cystatin C replace creatinine to estimate glomerular filtration rate? Am J Nephrol. 2007;27:197-205.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies